Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

2.

Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.

Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM.

J Infect Dis. 2010 May 1;201(9):1303-7. doi: 10.1086/651618.

3.

Update of the drug resistance mutations in HIV-1: December 2009.

Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2009 Dec;17(5):138-45. Review. No abstract available.

4.

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.

PENTA Steering Committee, Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, Bunupuradah T, Hainaut M, Della Negra M, Pena MJ, Amador JT, Gattinara GC, Compagnucci A, Faye A, Giaquinto C, Gibb DM, Gandhi K, Forcat S, Buckberry K, Harper L, Königs C, Patel D, Bastiaans D.

HIV Med. 2009 Nov;10(10):591-613. doi: 10.1111/j.1468-1293.2009.00759.x.

5.
6.

Class-sparing regimens for initial treatment of HIV-1 infection.

Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team.

N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609.

7.

HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004.

Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, Riordon A, Lyall H, Tookey P, Butler K, Sabin CA, Gibb D, Pillay D; Collaborative HIV Paediatric Study; UK Collaborative Group on HIV Drug Resistance.

Pediatr Infect Dis J. 2008 May;27(5):457-9. doi: 10.1097/INF.0b013e3181646d6f.

PMID:
18382385
8.

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.

von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

Arch Intern Med. 2007 Sep 10;167(16):1782-90.

PMID:
17846398
9.

A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115.

Riddler SA, Jiang H, Tenorio A, Huang H, Kuritzkes DR, Acosta EP, Landay A, Bastow B, Haas DW, Tashima KT, Jain MK, Deeks SG, Bartlett JA.

Antivir Ther. 2007;12(4):531-41.

PMID:
17668562
10.

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.

Green H, Gibb DM, Walker AS, Pillay D, Butler K, Candeias F, Castelli-Gattinara G, Compagnucci A, Della Negra M, de Rossi A, Feiterna-Sperling C, Giaquinto C, Harper L, Levy J, Saidi Y, Wintergerst U; Paediatric European Network for the Treatment of AIDS (PENTA).

AIDS. 2007 May 11;21(8):947-55.

PMID:
17457088
11.

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

INITIO Trial International Co-ordinating Committee, Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, Floridia M, Girard PM, Goodall RL, Hooker MH, Mijch A, Meiffredy V, Salzberger B.

Lancet. 2006 Jul 22;368(9532):287-98.

PMID:
16860698
12.

Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom.

Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, Evans B; UK Collaborative Group on HIV Drug Resistance.

J Infect Dis. 2005 Sep 15;192(6):967-73. Epub 2005 Aug 12.

13.

A trial of three antiretroviral regimens in HIV-1-infected children.

Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL; PACTG 356 Investigators.

N Engl J Med. 2004 Jun 10;350(24):2471-80.

14.

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.

Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, Benson C, King KR, Murphy RL, Brun SC.

AIDS. 2004 Mar 26;18(5):775-9.

PMID:
15075512
15.

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2304-15.

16.

Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants.

Faye A, Bertone C, Teglas JP, Chaix ML, Douard D, Firtion G, Thuret I, Dollfus C, Monpoux F, Floch C, Nicolas J, Vilmer E, Rouzioux C, Mayaux MJ, Blanche S; French Perinatal Study.

Pediatr Infect Dis J. 2002 Jun;21(6):518-25.

PMID:
12182375
17.

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team.

N Engl J Med. 2002 Jun 27;346(26):2039-46.

20.

Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.

Vigouroux C, Gharakhanian S, Salhi Y, Nguyên TH, Adda N, Rozenbaum W, Capeau J.

Diabetes Metab. 1999 Nov;25(5):383-92. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk